Advanced search

A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.

(2002) DIABETES CARE. 25(2). p.303-308
Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
LAMOTTE, M, Lieven Annemans, A LEFEVER, M NECHELPUT, and J MASURE. 2002. “A Health Economic Model to Assess the Long-term Effects and Cost-effectiveness of Orlistat in Obese Type 2 Diabetic Patients.” Diabetes Care 25 (2): 303–308.
APA
LAMOTTE, M., Annemans, L., LEFEVER, A., NECHELPUT, M., & MASURE, J. (2002). A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. DIABETES CARE, 25(2), 303–308.
Vancouver
1.
LAMOTTE M, Annemans L, LEFEVER A, NECHELPUT M, MASURE J. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. DIABETES CARE. 2002;25(2):303–8.
MLA
LAMOTTE, M, Lieven Annemans, A LEFEVER, et al. “A Health Economic Model to Assess the Long-term Effects and Cost-effectiveness of Orlistat in Obese Type 2 Diabetic Patients.” DIABETES CARE 25.2 (2002): 303–308. Print.
@article{165892,
  author       = {LAMOTTE, M and Annemans, Lieven and LEFEVER, A and NECHELPUT, M and MASURE, J},
  issn         = {0149-5992},
  journal      = {DIABETES CARE},
  language     = {eng},
  number       = {2},
  pages        = {303--308},
  title        = {A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.},
  volume       = {25},
  year         = {2002},
}

Web of Science
Times cited: